BILL ANALYSIS Ó
SENATE COMMITTEE ON APPROPRIATIONS
Senator Ricardo Lara, Chair
2015 - 2016 Regular Session
SB 1095 (Pan) - Newborn screening program
-----------------------------------------------------------------
| |
| |
| |
-----------------------------------------------------------------
|--------------------------------+--------------------------------|
| | |
|Version: February 17, 2016 |Policy Vote: HEALTH 9 - 0 |
| | |
|--------------------------------+--------------------------------|
| | |
|Urgency: No |Mandate: No |
| | |
|--------------------------------+--------------------------------|
| | |
|Hearing Date: May 27, 2016 |Consultant: Brendan McCarthy |
| | |
-----------------------------------------------------------------
Bill
Summary: SB 1095 would require the Department of Public Health
to expand the existing newborn screening program to include any
condition that has been adopted by the federal Recommended
Uniform Screening Panel.
*********** ANALYSIS ADDENDUM - SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on May 27, 2016
Fiscal
Impact:
One-time costs of $2.4 million and ongoing costs of $4.3
million per year to screen for two diseases (MPS-1 and Pompe
disease) that have already been approved for inclusion in the
federal Recommended Uniform Screening Panel (Genetic Disease
Testing Fund). The ongoing costs above would cover initial
screening tests, follow up tests for positive results, and
initial case management for confirmed diagnoses. Adding these
SB 1095 (Pan) Page 1 of
?
two conditions would require an increase in the existing $113
fee charged for screening by about $9. Most health insurance,
including Medi-Cal, cover the costs of the screening fee.
Ongoing costs of about $2.5 million per year for coverage of
the increased screening fee by the Medi-Cal program (General
Fund and federal funds). Medi-Cal covers the cost of the
screening exam and Medi-Cal pays for about 50% of the births
in the state.
Unknown future costs to include additional diseases in the
state's newborn screening program as they are added to the
federal Recommended Uniform Screening Panel (Genetic Disease
Testing Fund). The costs to include additional diseases will
vary depending on the specific costs for testing of that
disease. In recent years, anticipated costs to include
additional diseases in the state's newborn screening program
have generally been in the low millions per condition, per
year.
Likely long-term savings due to improved clinical outcomes
from early testing and treatment (various funds). When
considering whether to include additional diseases in the
Recommended Uniform Screening Panel, the federal advisory
committee considers issues such as the reliability of the
screening test, the availability of treatments, the benefits
of early diagnosis, and the anticipated impact on health
outcomes from additional screening. Specific information about
the long-term impacts on health outcomes or avoided health
care costs are often not available, because the diseases that
are considered for inclusion are rare and treatments are
evolving rapidly. However, new diseases are added when the
advisory panel finds that there are benefits from screening,
primarily the ability to avoid long-term health consequences
with early intervention. Therefore, it is reasonable to
believe that including additional diseases that have been
approved by the federal government will reduce state health
care spending in the long-run.
Author
Amendments: make technical corrections.
SB 1095 (Pan) Page 2 of
?
-- END --